Compugen (NASDAQ:CGEN – Get Rating) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.01, Briefing.com reports. During the same quarter last year, the business posted ($0.11) earnings per share.
Compugen Stock Down 5.8 %
CGEN traded down $0.09 during trading on Friday, hitting $1.46. The company had a trading volume of 1,674,531 shares, compared to its average volume of 913,445. The company has a market capitalization of $99.89 million, a PE ratio of -3.67 and a beta of 2.10. Compugen has a one year low of $1.39 and a one year high of $7.48. The firm’s 50-day moving average price is $1.85 and its 200 day moving average price is $2.51.
Institutional Investors Weigh In On Compugen
Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in Compugen during the 1st quarter worth about $37,000. Advisor Group Holdings Inc. lifted its position in Compugen by 29.3% during the 1st quarter. Advisor Group Holdings Inc. now owns 27,241 shares of the biotechnology company’s stock worth $87,000 after buying an additional 6,174 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Compugen by 23.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 33,260 shares of the biotechnology company’s stock worth $111,000 after buying an additional 6,299 shares in the last quarter. XTX Topco Ltd lifted its position in Compugen by 23.7% during the 1st quarter. XTX Topco Ltd now owns 44,918 shares of the biotechnology company’s stock worth $145,000 after buying an additional 8,615 shares in the last quarter. Finally, Panagora Asset Management Inc. bought a new stake in Compugen during the 1st quarter worth about $152,000.
Wall Street Analyst Weigh In
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on Compugen (CGEN)
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
- BJ’s Wholesale Club Stock Has More Room to Grow
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.